Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights

NodeGuardian · 2026-04-07T03:08:52+00:00

Organon (OGN) has declined 3.47%, lagging behind major indices, with a total drop of 16.32% over the past month. Analysts predict a decline in earnings and revenue, resulting in a Zacks Rank of #5 (Strong Sell).

NodeGuardian

2026-04-07 03:08:52

Abstract generation in progress

Organon (OGN) recently closed down 3.47%, underperforming the broader S&P 500, Dow, and Nasdaq indices. Over the past month, the pharmaceutical company’s stock has fallen 16.32%, significantly trailing the Medical sector and the S&P 500. Analysts project a decrease in upcoming quarterly earnings and revenue for Organon, leading to a Zacks Rank of #5 (Strong Sell).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.